Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial.

Date publication

janvier 2026

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel

Tous les auteurs :
Mirghani H, Aupérin A, Even C, Larive A, Fayette J, Geoffrois L, Clatot F, Calderon B, Tao Y, Nguyen F, Fabiano E, Kreps S, Gaultier AL, Bidault F, Puech J, Morin B, Picavet L, Tartour E, Ben Hariz A, Chevrot M, Monard L, Veyer D, Badoual C, Péré H, Blanchard P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41570275

Résumé

Patients with human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) and advanced stage and/or significant smoking history are at higher risk of relapse. Induction immunotherapy before chemoradiation (CRT) may improve outcomes. This randomized phase II trial assessed the feasibility and safety of induction nivolumab before CRT in this high-risk population.

Référence

J Clin Oncol. 2026 01 22;:JCO2500835